Am J Transplant, Volume 22, Suppl 3 Archives - Page 131 of 190 - ATC Abstracts

2022 American Transplant Congress
Impact of End-of-Chain Kidney Allocation on Access to Kidney Transplantation of Minority Patients: Implications for Reducing Disparities
J. Wade¹, K. Rancourt², A. Anane², A. Landeen², J. U. Singh³, X. Ye³, J. Tremaglio³, Z. Ebcioglu³, R. Kent³, B. Emmanuel⁴, G. Morgan⁴, O. K. Serrano⁴, W. Dar⁴
¹Department of Surgery, Surgical Research Program, Hartford Hospital, Hartford, CT, ²Hartford Hospital Transplant & Comprehensive Liver Center, Hartford, CT, ³Department of Medicine, Hartford Hospital Transplant & Comprehensive Liver Center, Hartford, CT, ⁴Department of Surgery, Hartford Hospital Transplant & Comprehensive Liver Center, Hartford, CT
*Purpose: Disparities in access to kidney transplantation (KT) among non-White patients is well-known, especially as it relates to living donor kidney transplantation (LDKT). We investigated…
2022 American Transplant Congress
Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients
A. Han¹, E. Cho¹, H. Y. Woo¹, C. Ara¹, H. Lee², Y. Kim³, Y. Park⁴, J. Oh⁴, S. Min¹, J. Ha¹
¹Department of Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, ²Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Nephrology, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Clnical Pharmacology, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Previous twice-a-day tacrolimus formulations available were capsular and of limited dose formulations (0.5mg, 1mg). Recently a new tablet formulation of tacrolimus with more diverse…
2022 American Transplant Congress
The Promise Of Tolerance In Living Donor Kidney Transplant (LDKT): A Retrospective, Real-world Assessment Of The Safety And Efficacy Of LDKT With FCR001 Investigational Cell-therapy Compared With Standard Of Care (SOC)
N. Krieger¹, J. R. Leventhal², B. Ho³, M. Richards⁴, D. Schaumberg⁴, S. Ildstad⁵, D. Axelrod⁶
¹Talaris Therapeutics, Inc, Wellesley, MA, ²SURGERY, Northwestern Medicine, Chicago, IL, ³Comprehensive Transplant Ctr, Chicago, IL, ⁴Evidera, Bethesda, MD, ⁵Talaris Therapeutics, Inc., Louisville, KY, ⁶University of Iowa, Iowa City, IA
*Purpose: FCR001 (FCR) is a cell therapy derived from mobilized donor PBMCs including hematopoietic progenitor cells, facilitating cells, and αβ T cells, intended to establish…
2022 American Transplant Congress
Analytical Evaluation and Comparison to STR of an Accurate and Sensitive Microchimerism Monitoring Tool for Liver Transplant Recipients
A. S. Kothari¹, C. Egidio¹, J. Miles², N. Gulbahce¹, S. Dholakia³, M. Grskovic⁴
¹Clinical Development, CareDx, South San Francisco, CA, ²Medical Affairs, CareDx, Brooklyn, NY, ³Medical Affairs, CareDx, South San Francisco, CA, ⁴CareDx, Brisbane, CA
*Purpose: Peripheral blood chimerism is associated with clinically relevant events post liver transplantation (LT). Accurate quantification of donor chimerism in LT recipients with ultra-sensitive chimerism…
2022 American Transplant Congress
A Three-gene Peripheral Blood Potential Diagnosis Signature Associated With Autophagy For Antibody-mediated Rejection In Renal Transplantation
Y. Wang, Y. Xu, H. Zhang, X. Hu
Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
*Purpose: Antibody-mediated rejection (AMR) is emerging as a major cause of graft loss in renal transplantation. Nowadays, non-invasive diagnosis of AMR with high accuracy is…
2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
S. Jordan¹, A. P. Limaye², B. Fischbach³, P. Sood⁴, S. Collette⁵, L. Gasink⁶, M. W. Fordyce⁷, C. J. Lin⁷, M. Hodges⁶, D. C. Brennan⁸
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Washington, Seattle, WA, ³Dallas Nephrology Associates, Inc, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ⁶previous employee/consultant for Amplyx Pharmaceuticals, San Diego, CA, ⁷Vera Therapeutics, Inc, Brisbane, CA, ⁸Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…
2022 American Transplant Congress
Superoxide in Cardiac Allografts from Donors After Circulatory Death
M. Urban¹, T. Bruett², K. F. Duncan¹, N. W. Markin³, M. M. Chacon³, M. C. Zimmerman⁴
¹Department of Surgery. Division of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, ²College of Medicine. Department of Cellular and Integtrative Physiology., University of Nebraska Medical Center, Omaha, NE, ³Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE
*Purpose: Quality of cardiac allografts from donors after circulatory death (DCD) is adversely impacted by warm ischemia and subsequent reperfusion during organ resuscitation. Post-transplant myocardial…
2022 American Transplant Congress
Decellularized Human Pancreatic Extracellular Matrix-Based Physiomimetic Microenvironment for Human Islet Culture
A. Asthana¹, D. Chaimov¹, R. Tamburrini², S. J. Walker³, G. Orlando¹
¹Wake Forest Baptist Medical Center, Winston-Salem, NC, ²University of Wisconsin Hospital and Clinics, Madison, WI, ³Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC
*Purpose: Maintenance of human islet viability and function ex vivo can be a significant bottleneck for both regenerative medicine as well as tissue engineering applications.…
2022 American Transplant Congress
Selective Vascular Decellularization and Endothelial Cells Replacement as a Strategy to Reduce Reperfusion Injury in Bioartificial Organs
G. Haeublein¹, G. Lombardi¹, F. Caro¹, R. Carla¹, D. Guerrieri¹, C. Incardona², D. Casadei³, E. Chuluyan¹
¹CEFYBO, Buenos Aires, Argentina, ²GADOR S.A., Buenos Aires, Argentina, ³Fundación Argentina de Trasplante, Tercer Milenio, Buenos Aires, Argentina
*Purpose: The number of kidney transplants performed each year cannot meet the increasing demand of these organs. Several strategies aim to increasing the offer of…
2022 American Transplant Congress
Enhancing Early Nerve Regeneration from Reconstruction of a Segmental Nerve Injury with Polyethylene Glycol
A. Bernal¹, C. Hinshaw¹, J. Hinshaw¹, C. Yang², S. Margaux¹, W. Zhang¹, J. Nuelle¹, C. Sabbag¹, G. Bittner², J. Shores³, E. Weitzel¹, J. Alderete¹
¹RESTOR FUSE Nerve Reconstruction Consortium, US Army Institute of Surgical Research/59th MDW, San Antonio, TX, ²University of Texas at Austin, Austin, TX, ³John Hopkins University, Baltimore, MD
*Purpose: Despite advancements in understanding and treating peripheral nerve injuries (PNIs), restoration of lost motor and sensory functions remain poor using current methods of clinical…